At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
X4P-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating X4P-001 and axitinib for Clear Cell Renal Cell Carcinoma. Completed, enrolled 74 participants across 20 sites in 2 countries.
Detailed Summary
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClear Cell Renal Cell Carcinoma
CountriesSouth Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartApr 2016
Primary CompletionApr 2022
TodayJul 2026
First PostedJan 29, 2016
Enrollment StartApr 27, 2016
Primary CompletionApr 14, 2022
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 10.4 years ago
Interventions
X4P-001drug
Continuous, oral dosing
axitinibdrug
Continuous, oral dosing